The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwMPN 2026 | MPN Progression Registry: insights into the work of the MPN Research Foundation
In this roundtable discussion, David Shoultz, MPN Research Foundation, Chicago, IL, Kapila Viges, MPN Research Foundation, Chicago, IL, Douglas Tremblay, MD, Icahn School of Medicine at Mount Sinai, New York, NY, and Raajit Rampal, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, discuss the MPN Progression Registry, launched by the MPN Research Foundation in September 2025 to address patients’ uncertainty about disease progression. The experts highlight the registry’s direct-to-patient model, which has enrolled patients with myeloproliferative neoplasms (MPNs), and captures both patient-reported outcomes and long-term electronic medical record data. Kapila Viges provides an overview of the vision for the registry, and Dr Rampal and Dr Tremblay comment on its potential to identify surrogate biomarkers of progression and inform trial endpoints. This roundtable discussion took place at the 4th International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS/iwMPN) 2026, held in Washington, D.C.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
